Cardioprotection from Moderate Drinking Is Limited to People with Unhealthful Behaviors
Nonsmokers who ate healthful diets and exercised didn't benefit from alcohol.
In observational studies, researchers have found an association between moderate drinking and lower risk for myocardial infarction, but less is known about whether this benefit is limited to select groups. Researchers in London prospectively followed 9655 middle-aged adult civil servants (mean age, 44; none with known MI at enrollment) for a median of 17 years.
Subjects were characterized according to number of unhealthful behaviors (smoking, lack of exercise, poor diet). Among people who reported regular physical activity, daily fruit and vegetable consumption, and no smoking, alcohol use had no effect on incidence of fatal coronary heart disease or nonfatal MI in analyses that were adjusted for age, sex, and socioeconomic status. Among participants with two or three unhealthful behaviors, moderate alcohol intake (8–112 g, or about 1–9 standard U.S. drinks weekly) was associated with half the risk for CHD; in addition, adjusting for diabetes, angina, hypertension, and cardiovascular medication use yielded similar results.
Comment:
Even if moderate drinking lowers risk for CHD (a hypothesis that has not been confirmed yet in clinical trials), alcohol ingestion appears to have no such benefit for people who exercise, eat fruits and vegetables, and do not smoke. The authors cite one large cohort study, done in the U.S., with similar results. Therefore, they recommend that this typically overlooked variability in the effect of moderate drinking be emphasized in public health messages and advice about alcohol use. Such a message — which would acknowledge potential benefits among people with certain unhealthful behaviors — also would emphasize lack of benefit in others and the importance of healthful behaviors. The message is complicated further by the lack of controlled trials, by research that suggests benefits accrue mainly to those with genetic predispositions to alcoholism, and by harms associated with moderate drinking (e.g., excess risk for certain cancers).
—
Richard Saitz, MD, MPH, FACP, FASAM
Published in Journal Watch General Medicine December 18, 2008
Citation(s):
Britton A et al. Who benefits most from the cardioprotective properties of alcohol consumption — Health freaks or couch potatoes? J Epidemiol Community Health 2008 Oct; 62:905.
2008年12月18日 星期四
2008年12月17日 星期三
OHCA 要不要用血栓溶解劑?目前證據不 favor...
Thrombolysis during Resuscitation
NEJM 2008 Dec. B.W. Bottiger et al: Thrombolysis during Resuscitation for Out-of-Hospital Cardiac Arrest.
In this randomized, double-blind, multicenter trial, adult patients with witnessed out-of-hospital cardiac arrest were assigned to receive either tenecteplase (thrombolytic agent) or placebo during resuscitation. The use of heparin, clopidogrel, ticlodipine, and aspirin were discouraged and the use of glycoprotein IIb/IIIa inhibitors was not permitted in this study. The researchers observed no significant differences between the tenecteplase and placebo groups in the efficacy end points that were evaluated, including the primary end point of 30-day survival and the secondary end points of return of spontaneous circulation, hospital admission, 24-hour survival, survival to hospital discharge, and neurologic outcome. However, the researchers do state the following: “Our findings do not suggest that thrombolytic therapy should be withheld in patients with cardiac arrest if the primary pathologic condition is known to be responsive to such treatment.”
-----
Peals
-----
Clinical Pearl Intracranial Hemorrhage and Thrombolysis
One of the biggest risk factors associated with the use of thrombolytic agents is intracranial hemorrhage. In this study, intracranial hemorrhage occurred with significantly greater frequency in the tenecteplase group (14 of 518 [2.7%]) than in the placebo group (2 of the 514 [0.4%], P=0.006). Four patients with intracranial hemorrhage (all in the tenecteplase group) were symptomatic.
Guidelines for Use of Thrombolytics in Cardiac Arrest
Current cardiopulmonary-resuscitation guidelines state that thrombolytic therapy should be considered in adult patients who have cardiac arrest with pulmonary embolism but there are insufficient data to make a recommendation for or against the use of thrombolysis in cardiac arrest. (American Heart Association Guidelines, Circulation, 2005.)
NEJM 2008 Dec. B.W. Bottiger et al: Thrombolysis during Resuscitation for Out-of-Hospital Cardiac Arrest.
In this randomized, double-blind, multicenter trial, adult patients with witnessed out-of-hospital cardiac arrest were assigned to receive either tenecteplase (thrombolytic agent) or placebo during resuscitation. The use of heparin, clopidogrel, ticlodipine, and aspirin were discouraged and the use of glycoprotein IIb/IIIa inhibitors was not permitted in this study. The researchers observed no significant differences between the tenecteplase and placebo groups in the efficacy end points that were evaluated, including the primary end point of 30-day survival and the secondary end points of return of spontaneous circulation, hospital admission, 24-hour survival, survival to hospital discharge, and neurologic outcome. However, the researchers do state the following: “Our findings do not suggest that thrombolytic therapy should be withheld in patients with cardiac arrest if the primary pathologic condition is known to be responsive to such treatment.”
-----
Peals
-----
Clinical Pearl Intracranial Hemorrhage and Thrombolysis
One of the biggest risk factors associated with the use of thrombolytic agents is intracranial hemorrhage. In this study, intracranial hemorrhage occurred with significantly greater frequency in the tenecteplase group (14 of 518 [2.7%]) than in the placebo group (2 of the 514 [0.4%], P=0.006). Four patients with intracranial hemorrhage (all in the tenecteplase group) were symptomatic.
Guidelines for Use of Thrombolytics in Cardiac Arrest
Current cardiopulmonary-resuscitation guidelines state that thrombolytic therapy should be considered in adult patients who have cardiac arrest with pulmonary embolism but there are insufficient data to make a recommendation for or against the use of thrombolysis in cardiac arrest. (American Heart Association Guidelines, Circulation, 2005.)
2008年12月12日 星期五
Blowout fracture 不必立即手術...
這可是曾經出現在急專考古題的題目喔!
Comparison of Orbital Fracture Repair Performed Within 14 Days Versus 15 to 29 Days After Trauma.
Ophthalmic Plastic & Reconstructive Surgery. 24(6):437-443
Purpose: To examine whether orbital floor and/or medial wall fracture repair delayed for 15 to 29 days is as effective as early surgery.
Methods: A retrospective review is reported comparing outcomes of early fracture repairs (performed 1-14 days after trauma) to delayed fracture repairs (performed 15-29 days after trauma). Ocular motility, diplopia, and time to resolution of diplopia postoperatively are the main endpoints.
Results: Fifty-eight patients were included in the study: 36 underwent early fracture repair (average 9 days after trauma) and 22 underwent delayed fracture repair (average 19 days after trauma). Ocular motility was equivalent in both groups, both before and after surgery. Patient reports of diplopia and frequency of strabisumus surgery were also equivalent in both groups. The time to resolution or stability of diplopia postoperatively is independent of the time to surgery within the first 29 days after trauma.
Conclusions: Although 14 days after trauma is commonly cited as a timeline target for orbital blowout repair, these data show that effective fracture repair can be performed up to 29 days after trauma. Patients with improving diplopia and at low risk for enophthalmos can therefore be observed for 3 to 4 weeks prior to undergoing surgery. This may help prevent unnecessary surgery in some cases. Fourteen days need not be considered a deadline for orbital floor and/or medial wall fracture repair.
Comparison of Orbital Fracture Repair Performed Within 14 Days Versus 15 to 29 Days After Trauma.
Ophthalmic Plastic & Reconstructive Surgery. 24(6):437-443
Purpose: To examine whether orbital floor and/or medial wall fracture repair delayed for 15 to 29 days is as effective as early surgery.
Methods: A retrospective review is reported comparing outcomes of early fracture repairs (performed 1-14 days after trauma) to delayed fracture repairs (performed 15-29 days after trauma). Ocular motility, diplopia, and time to resolution of diplopia postoperatively are the main endpoints.
Results: Fifty-eight patients were included in the study: 36 underwent early fracture repair (average 9 days after trauma) and 22 underwent delayed fracture repair (average 19 days after trauma). Ocular motility was equivalent in both groups, both before and after surgery. Patient reports of diplopia and frequency of strabisumus surgery were also equivalent in both groups. The time to resolution or stability of diplopia postoperatively is independent of the time to surgery within the first 29 days after trauma.
Conclusions: Although 14 days after trauma is commonly cited as a timeline target for orbital blowout repair, these data show that effective fracture repair can be performed up to 29 days after trauma. Patients with improving diplopia and at low risk for enophthalmos can therefore be observed for 3 to 4 weeks prior to undergoing surgery. This may help prevent unnecessary surgery in some cases. Fourteen days need not be considered a deadline for orbital floor and/or medial wall fracture repair.
2008年12月10日 星期三
流感之疫苗及用藥
Influenza Vaccine Guidelines
According to the Advisory Committee on Immunization Practices (ACIP), influenza vaccination is currently recommended for all persons 50 years of age or older, all children between 6 months and 18 years of age, and persons 19 to 49 years of age who have underlying medical conditions, are pregnant, are employed as health care workers, or are household contacts of high-risk persons (a group that includes all children in the household who are younger than 5 years of age). Infants younger than 6 months of age, who have the highest hospitalization rates, although ineligible for vaccination, can be protected by immunization of their mothers during pregnancy.
Influenza Treatment
The older adamantanes, amantadine, and rimantadine are currently not recommended for use in the United States because almost all influenza A (H3N2) viruses are resistant to them, and they are not effective against influenza B viruses. When influenza A (H1N1) viruses predominate, however, these drugs may still be useful if they are used in combination with a neuraminidase inhibitor. An increasing proportion of influenza A (H1N1) viruses are resistant to oseltamivir, the oral neuraminidase inhibitor, but not to zanamivir. Zanamivir is a neuraminidase inhibitor that is administered by active inhalation, a method that may not be practical for debilitated patients or for children younger than 7 years of age, and is contraindicated in those with reactive airway disease.
---
New England Journal of Medicine - Vol. 359, No. 24, December 11, 2008
According to the Advisory Committee on Immunization Practices (ACIP), influenza vaccination is currently recommended for all persons 50 years of age or older, all children between 6 months and 18 years of age, and persons 19 to 49 years of age who have underlying medical conditions, are pregnant, are employed as health care workers, or are household contacts of high-risk persons (a group that includes all children in the household who are younger than 5 years of age). Infants younger than 6 months of age, who have the highest hospitalization rates, although ineligible for vaccination, can be protected by immunization of their mothers during pregnancy.
Influenza Treatment
The older adamantanes, amantadine, and rimantadine are currently not recommended for use in the United States because almost all influenza A (H3N2) viruses are resistant to them, and they are not effective against influenza B viruses. When influenza A (H1N1) viruses predominate, however, these drugs may still be useful if they are used in combination with a neuraminidase inhibitor. An increasing proportion of influenza A (H1N1) viruses are resistant to oseltamivir, the oral neuraminidase inhibitor, but not to zanamivir. Zanamivir is a neuraminidase inhibitor that is administered by active inhalation, a method that may not be practical for debilitated patients or for children younger than 7 years of age, and is contraindicated in those with reactive airway disease.
---
New England Journal of Medicine - Vol. 359, No. 24, December 11, 2008
2008年12月9日 星期二
ECG可即時診斷ROSC後之STEMI
The Accuracy of an Out-of-Hospital 12-Lead ECG for the Detection of ST-Elevation Myocardial Infarction Immediately After Resuscitation
Study objective:
Severe myocardial ischemia is the leading cause of arrhythmic sudden cardiac death. It is unclear, however, in which percentage of patients sudden cardiac death is triggered by ST-elevation myocardial infarction (STEMI) and whether the diagnosis of STEMI can be reliably established immediately after resuscitation from out-of-hospital sudden cardiac death.
Methods:
A 12-lead ECG was registered after return of spontaneous circulation after cardiac arrest. After hospital admission, further ECG, creatine kinase MB, and troponin measures; results of coronary angiograms; and autopsies were evaluated to confirm the definitive diagnosis of STEMI.
Results:
Seventy-seven patients were included in our study (67% men, age 64 [14 to 93] years). STEMI was diagnosed in 44 patients. The diagnosis of myocardial infarction was confirmed in 84% of the 77 patients who survived to hospital admission. The sensitivity of the out-of-hospital ECG was 88% (95% confidence interval [CI] 74% to 96%), the specificity 69% (95% CI 51% to 83%), the positive predictive value 77% (95% CI 62% to 87%), and the negative predictive value 83% (95% CI 64% to 87%). The accuracy of the out-of-hospital ECG and that registered on admission was the same.
Conclusion:
The diagnosis of STEMI can be established in the field immediately after return of spontaneous circulation in most patients. This may enable an early decision about reperfusion therapy, ie, immediate out-ofhospital thrombolysis or targeted transfer for percutaneous coronary intervention. [Ann Emerg Med. 2008;52:658-664.]
Study objective:
Severe myocardial ischemia is the leading cause of arrhythmic sudden cardiac death. It is unclear, however, in which percentage of patients sudden cardiac death is triggered by ST-elevation myocardial infarction (STEMI) and whether the diagnosis of STEMI can be reliably established immediately after resuscitation from out-of-hospital sudden cardiac death.
Methods:
A 12-lead ECG was registered after return of spontaneous circulation after cardiac arrest. After hospital admission, further ECG, creatine kinase MB, and troponin measures; results of coronary angiograms; and autopsies were evaluated to confirm the definitive diagnosis of STEMI.
Results:
Seventy-seven patients were included in our study (67% men, age 64 [14 to 93] years). STEMI was diagnosed in 44 patients. The diagnosis of myocardial infarction was confirmed in 84% of the 77 patients who survived to hospital admission. The sensitivity of the out-of-hospital ECG was 88% (95% confidence interval [CI] 74% to 96%), the specificity 69% (95% CI 51% to 83%), the positive predictive value 77% (95% CI 62% to 87%), and the negative predictive value 83% (95% CI 64% to 87%). The accuracy of the out-of-hospital ECG and that registered on admission was the same.
Conclusion:
The diagnosis of STEMI can be established in the field immediately after return of spontaneous circulation in most patients. This may enable an early decision about reperfusion therapy, ie, immediate out-ofhospital thrombolysis or targeted transfer for percutaneous coronary intervention. [Ann Emerg Med. 2008;52:658-664.]
有3%的男性BAT會出現不明來源之free fluid
MDCT Evaluation of Blunt Abdominal Trauma: Clinical Significance of Free Intraperitoneal Fluid in Males with Absence of Identifiable Injury
OBJECTIVE.
The purpose of our study was to determine the clinical significance of the isolated finding of free intraperitoneal fluid on 64-MDCT in male patients who have undergone blunt trauma.
MATERIALS AND METHODS.
A retrospective study was performed of 669 consecutive male patients, ranging in age from 15 to 85 years, who underwent CT evaluation of the abdomen and pelvis at our level 1 trauma center over a 17-month period. Two radiologists evaluated the images for the presence of free intraperitoneal fluid and for an underlying cause. For patients with free intraperitoneal fluid, the mean attenuation and the size of the largest pocket of fluid on both portal venous and delayed phase images were measured for both those with and those without injury. For the patients who had free intraperitoneal fluid as an isolated finding, the electronic chart was reviewed to determine the clinical outcome, specifically whether these patients were observed, had short-interval follow-up imaging, or underwent exploratory laparotomy.
RESULTS.
Forty-eight of the 669 patients (7.2%) had free intraperitoneal fluid. Twenty-nine (4.3%) of these patients had an identifiable solid organ, bowel, bladder, or pelvic injury to explain the free fluid. In the remaining 19 (2.8%) patients, free fluid was an isolated finding. The size of the largest collection of fluid was smaller for patients without identifiable injury on portal venous phase (1,236 vs 348 mm2) and delayed phase (1,325 vs 298 mm2) images (p = 0.0015 and p < 0.0001, respectively). Fluid in patients without identifiable injury was also shown to be less dense. A statistically significant difference between the mean attenuation coefficients of the fluid in the patients with and without injury was also found on both the portal venous phase (45.1 vs 13.1 HU, p < 0.0001) and delayed phase (45.6 vs 20.8 HU, p < 0.0001) images. All 19 patients without identifiable injury were admitted for observation and discharged without surgical intervention.
CONCLUSION.
With 64 MDCT, the isolated finding of free intraperitoneal fluid in male patients who have undergone blunt trauma is seen in approximately 3% of patients. The size and mean attenuation coefficient measurements may add useful information regarding the clinical management of these patients, suggesting that small amounts of low-attenuation free fluid, in the absence of identifiable injury, may have no significant clinical implications.
---
DOI:10.2214/AJR.07.3347
AJR 2008; 191:1821-1826
American Journal of Roentgenology
OBJECTIVE.
The purpose of our study was to determine the clinical significance of the isolated finding of free intraperitoneal fluid on 64-MDCT in male patients who have undergone blunt trauma.
MATERIALS AND METHODS.
A retrospective study was performed of 669 consecutive male patients, ranging in age from 15 to 85 years, who underwent CT evaluation of the abdomen and pelvis at our level 1 trauma center over a 17-month period. Two radiologists evaluated the images for the presence of free intraperitoneal fluid and for an underlying cause. For patients with free intraperitoneal fluid, the mean attenuation and the size of the largest pocket of fluid on both portal venous and delayed phase images were measured for both those with and those without injury. For the patients who had free intraperitoneal fluid as an isolated finding, the electronic chart was reviewed to determine the clinical outcome, specifically whether these patients were observed, had short-interval follow-up imaging, or underwent exploratory laparotomy.
RESULTS.
Forty-eight of the 669 patients (7.2%) had free intraperitoneal fluid. Twenty-nine (4.3%) of these patients had an identifiable solid organ, bowel, bladder, or pelvic injury to explain the free fluid. In the remaining 19 (2.8%) patients, free fluid was an isolated finding. The size of the largest collection of fluid was smaller for patients without identifiable injury on portal venous phase (1,236 vs 348 mm2) and delayed phase (1,325 vs 298 mm2) images (p = 0.0015 and p < 0.0001, respectively). Fluid in patients without identifiable injury was also shown to be less dense. A statistically significant difference between the mean attenuation coefficients of the fluid in the patients with and without injury was also found on both the portal venous phase (45.1 vs 13.1 HU, p < 0.0001) and delayed phase (45.6 vs 20.8 HU, p < 0.0001) images. All 19 patients without identifiable injury were admitted for observation and discharged without surgical intervention.
CONCLUSION.
With 64 MDCT, the isolated finding of free intraperitoneal fluid in male patients who have undergone blunt trauma is seen in approximately 3% of patients. The size and mean attenuation coefficient measurements may add useful information regarding the clinical management of these patients, suggesting that small amounts of low-attenuation free fluid, in the absence of identifiable injury, may have no significant clinical implications.
---
DOI:10.2214/AJR.07.3347
AJR 2008; 191:1821-1826
American Journal of Roentgenology
2008年12月2日 星期二
Inhaled corticosteroid for COPD
CONTEXT: Recent studies of inhaled corticosteroid (ICS) therapy for managing stable chronic obstructive pulmonary disease (COPD) have yielded conflicting results regarding survival and risk of adverse events.
OBJECTIVE: To systematically review and quantitatively synthesize the effects of ICS therapy on mortality and adverse events in patients with stable COPD.
DATA SOURCES: Search of MEDLINE, CENTRAL, EMBASE, CINAHL, Web of Science, and PsychInfo through February 9, 2008. STUDY SELECTION: Eligible studies were double-blind, randomized controlled trials comparing ICS therapy for 6 or more months with nonsteroid inhaled therapy in patients with COPD.
DATA EXTRACTION: Two authors independently abstracted data including study characteristics, all-cause mortality, pneumonia, and bone fractures. The I(2) statistic was used to assess heterogeneity. Study-level data were pooled using a random-effects model (when I(2) > or = 50%) or a fixed-effects model (when I(2) < 50%). For the primary outcome of all-cause mortality at 1 year, our meta-analysis was powered to detect a 1.0% absolute difference in mortality, assuming a 2-sided alpha of .05 and power of 0.80.
RESULTS: Eleven eligible randomized controlled trials (14,426 participants) were included. In trials with mortality data, no difference was observed in 1-year all-cause mortality (128 deaths among 4636 patients in the treatment group and 148 deaths among 4597 patients in the control group; relative risk [RR], 0.86; 95% confidence interval [CI], 0.68-1.09; P = .20; I(2) = 0%). In the trials with data on pneumonia, ICS therapy was associated with a significantly higher incidence of pneumonia (777 cases among 5405 patients in the treatment group and 561 cases among 5371 patients in the control group; RR, 1.34; 95% CI, 1.03-1.75; P = .03; I(2) = 72%). Subgroup analyses indicated an increased risk of pneumonia in the following subgroups: highest ICS dose (RR, 1.46; 95% CI, 1.10-1.92; P = .008; I(2) = 78%), shorter duration of ICS use (RR, 2.12; 95% CI, 1.47-3.05; P < .001; I(2) = 0%), lowest baseline forced expiratory volume in the first second of expiration (RR, 1.90; 95% CI, 1.26-2.85; P = .002; I(2) = 0%), and combined ICS and bronchodilator therapy (RR, 1.57; 95% CI, 1.35-1.82; P < .001; I(2) = 24%).
CONCLUSIONS: Among patients with COPD, ICS therapy does not affect 1-year all-cause mortality. ICS therapy is associated with a higher risk of pneumonia. Future studies should determine whether specific subsets of patients with COPD benefit from ICS therapy.
---
Overall, the tension with adding inhaled corticosteroid will continue to be:
Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 Nov 26;300(20):2407-16.
OBJECTIVE: To systematically review and quantitatively synthesize the effects of ICS therapy on mortality and adverse events in patients with stable COPD.
DATA SOURCES: Search of MEDLINE, CENTRAL, EMBASE, CINAHL, Web of Science, and PsychInfo through February 9, 2008. STUDY SELECTION: Eligible studies were double-blind, randomized controlled trials comparing ICS therapy for 6 or more months with nonsteroid inhaled therapy in patients with COPD.
DATA EXTRACTION: Two authors independently abstracted data including study characteristics, all-cause mortality, pneumonia, and bone fractures. The I(2) statistic was used to assess heterogeneity. Study-level data were pooled using a random-effects model (when I(2) > or = 50%) or a fixed-effects model (when I(2) < 50%). For the primary outcome of all-cause mortality at 1 year, our meta-analysis was powered to detect a 1.0% absolute difference in mortality, assuming a 2-sided alpha of .05 and power of 0.80.
RESULTS: Eleven eligible randomized controlled trials (14,426 participants) were included. In trials with mortality data, no difference was observed in 1-year all-cause mortality (128 deaths among 4636 patients in the treatment group and 148 deaths among 4597 patients in the control group; relative risk [RR], 0.86; 95% confidence interval [CI], 0.68-1.09; P = .20; I(2) = 0%). In the trials with data on pneumonia, ICS therapy was associated with a significantly higher incidence of pneumonia (777 cases among 5405 patients in the treatment group and 561 cases among 5371 patients in the control group; RR, 1.34; 95% CI, 1.03-1.75; P = .03; I(2) = 72%). Subgroup analyses indicated an increased risk of pneumonia in the following subgroups: highest ICS dose (RR, 1.46; 95% CI, 1.10-1.92; P = .008; I(2) = 78%), shorter duration of ICS use (RR, 2.12; 95% CI, 1.47-3.05; P < .001; I(2) = 0%), lowest baseline forced expiratory volume in the first second of expiration (RR, 1.90; 95% CI, 1.26-2.85; P = .002; I(2) = 0%), and combined ICS and bronchodilator therapy (RR, 1.57; 95% CI, 1.35-1.82; P < .001; I(2) = 24%).
CONCLUSIONS: Among patients with COPD, ICS therapy does not affect 1-year all-cause mortality. ICS therapy is associated with a higher risk of pneumonia. Future studies should determine whether specific subsets of patients with COPD benefit from ICS therapy.
---
Overall, the tension with adding inhaled corticosteroid will continue to be:
- less exacerbations of COPD
- better quality of life
- more pneumonia without increased mortality
Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 Nov 26;300(20):2407-16.
訂閱:
文章 (Atom)